Summary & Overview

Headaches without Major Complication or Comorbidity: Inpatient Reimbursement Overview

DRG 103 groups inpatient admissions for headache without Major Complication or Comorbidity, addressing low-acuity headache diagnoses that do not drive high resource use. Accurate classification into this Diagnosis-Related Group matters for inpatient reimbursement because it determines the bundled Medicare payment for the episode of care.

Headaches without MCCDRG Headaches without MCCDRG 103Diagnosis-Related GroupInpatient ReimbursementMedicareNeurologyEmergency MedicineHospital Medicine

DRG 103 Overview

DRG 103 covers hospital inpatient admissions for primary diagnoses of headache when no Major Complication or Comorbidity and no Complication or Comorbidity are present. This category typically includes conditions such as primary headache disorders and acute headache presentations that do not require major procedures or intensive resource use. It matters for Medicare payment because it groups like clinical cases to determine the bundled payment amount for the inpatient stay. Understanding this classification helps clarify expected reimbursement levels for low-acuity headache admissions.

National Payment Rates

Across commercial payers the observed rate range runs from about $370 up to $28K, with mean values spanning roughly $7.8K to $14K depending on payer. The widest spread is seen between BCBS’s minimums and Anthem’s maximums, producing the largest overall dispersion among payers. See the table and chart below for payer-level detail.

Mean Rates by Payer — National — DRG 103

The CMS 2023 data represent national Medicare FFS inpatient payments published in the CMS Provider Utilization and Payment Data program. The table below shows average total payment, average submitted covered charges, average Medicare payment amount, and total discharges for DRG in 2023.

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Payer rates for DRG 103 in Alaska cluster tightly for Anthem and Blue Cross Blue Shield at $13K, while Cigna presents a wider range with a mean of $20K and a max of $34K, producing the state-level span from $13K to $34K. This results in a notable deviation from national averages where Cigna’s Alaska mean exceeds typical national medians. See the table and chart below for the payer-level detail.

Key Insights for Alaska

Anthem is the highest paying payer in Alaska at $13K, while Blue Cross Blue Shield is tied at the lowest reported rate of $13K.
Cigna shows the widest spread in Alaska with a mean of $20K and a max of $34K, a meaningful premium above national medians for similar payers.

Clinical Trials

Acute emergency management trials evaluating rapid-acting therapies and protocols for severe primary headache presentations (including migraine with prominent nausea or intractable pain) that present to the emergency department. These studies enroll adults who are admitted under DRG 103 for acute headache without major comorbid conditions and compare time-to-pain-relief, need for rescue medication, and short-term disposition (observation versus discharge). Results inform emergency care pathways, reduce length of stay and resource utilization, and are directly relevant to hospital providers and payers focused on efficient, guideline-concordant acute management.
Comparative effectiveness studies of outpatient preventive strategies and care pathways initiated during hospitalization for recurrent headache disorders. These trials enroll patients admitted with disabling primary headache who have frequent prior attacks but no major complicating diagnoses, randomizing to different preventive regimens or integrated care models (e.g., neurology follow-up plus structured education versus usual care). Findings are important for determining which post-discharge interventions reduce readmissions, subsequent ED visits, and overall costs for the DRG cohort while improving functional outcomes.
Health services and outcomes research assessing disposition, resource use, and patient-reported outcomes for hospitalized patients with headache without MCC, including risk prediction and care coordination interventions. These observational and implementation studies use real-world hospital data to identify predictors of prolonged stay, return visits, and work/activity impairment, and to evaluate care coordination efforts (timely specialist consults, standardized order sets). Payers and hospital administrators use this evidence to target interventions that lower unnecessary admissions and optimize reimbursement and quality metrics for this DRG.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$8.8K	$46K	$5.8K	6.4K

Acute emergency management trials evaluating rapid-acting therapies and protocols for severe primary headache presentations (including migraine with prominent nausea or intractable pain) that present to the emergency department. These studies enroll adults who are admitted under DRG 103 for acute headache without major comorbid conditions and compare time-to-pain-relief, need for rescue medication, and short-term disposition (observation versus discharge). Results inform emergency care pathways, reduce length of stay and resource utilization, and are directly relevant to hospital providers and payers focused on efficient, guideline-concordant acute management.
Comparative effectiveness studies of outpatient preventive strategies and care pathways initiated during hospitalization for recurrent headache disorders. These trials enroll patients admitted with disabling primary headache who have frequent prior attacks but no major complicating diagnoses, randomizing to different preventive regimens or integrated care models (e.g., neurology follow-up plus structured education versus usual care). Findings are important for determining which post-discharge interventions reduce readmissions, subsequent ED visits, and overall costs for the DRG cohort while improving functional outcomes.
Health services and outcomes research assessing disposition, resource use, and patient-reported outcomes for hospitalized patients with headache without MCC, including risk prediction and care coordination interventions. These observational and implementation studies use real-world hospital data to identify predictors of prolonged stay, return visits, and work/activity impairment, and to evaluate care coordination efforts (timely specialist consults, standardized order sets). Payers and hospital administrators use this evidence to target interventions that lower unnecessary admissions and optimize reimbursement and quality metrics for this DRG.

OpenPayer

Summary & Overview

Headaches without Major Complication or Comorbidity: Inpatient Reimbursement Overview

DRG 103 Overview

National Payment Rates

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes